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and McInnes, 2007); EAAT2a (the protein originally called EAAT2) 
is more abundant and more closely related to synapses than the 
other isoforms (Lauriat and McInnes, 2007). In rodents, EAAT2a 
is expressed by astrocytes (Danbolt et al., 1992; Levy et al., 1993; 
Rothstein et al., 1994; Torp et al., 1994; Lehre et al., 1995; Minelli 
et al., 2001; Melone et al., 2009; de Vivo et al., 2010), and, albeit 
at lower levels, by neurons (Chen et al., 2004; Furness et al., 2008; 
Holmseth et al., 2009; Melone et al., 2009; see also Berger et al., 
2005; and de Vivo et al., 2010). In both astrocytic processes and 
axon terminals, most EAAT2a is perisynaptic, i.e., in the plasma 
membrane region extending 200–250 nm from the edge of the 
active zone (Melone et al., 2009), a position suitable for modulating 
Glu concentration in the cleft. Recently, we showed that enhancing 
transcription of GLT-1 gene increases the density of gold particles 
coding for EAAT2 near and within active zones of hippocampal 
mossy fiber (MF) terminals and in astrocytic processes and that 
this effect is associated with a significant impairment of long-
term depression and long-term potentiation at MF–CA3 synapses 
(Omrani et al., 2009). Thus, based on studies in rodents, regu-
lation of EAAT2-mediated glutamate uptake may be important 
for maintaining the level of synaptic strength during long-term 
changes in synaptic efficacy (Katagiri et al., 2001; Levenson et al., 
2002; Omrani et al., 2009).
EAAT2 has been associated with the pathophysiology of several 
neuropsychiatric diseases, including amyotrophic lateral sclerosis, 
Alzheimer’s disease, schizophrenia, Huntington’s disease,   epilepsy, 
INTRODUCTION
Glutamate is the major neurotransmitter in the cerebral cortex. 
Beyond its role in fast excitatory signaling, it is important in syn-
aptogenesis, synaptic plasticity and in the pathophysiology of 
neuropsychiatric diseases (Conti and Hicks, 1996). Glutamate-
mediated transmission depends on highly regulated mechanisms 
operating at pre- and post-synaptic sites, and on mechanism 
responsible for rapid clearance of the transmitter at the cleft, i.e., 
passive diffusion, and the action of high-affinity excitatory amino 
acid transporters (EAATs; Conti and Weinberg, 1999). Much evi-
dence has demonstrated that EAATs maintain physiological levels 
of glutamate, contribute to sculpting excitatory post-synaptic cur-
rents and modulating glutamate diffusion (Conti and Weinberg, 
1999; Rusakov et al., 1999; Danbolt, 2001; Torres and Amara, 2007; 
Tzingounis and Wadiche, 2007).
Five EAATs have been characterized in the mammalian cen-
tral nervous system: EAAT1 (GLAST; SLC1A3), EAAT2 (GLT-1; 
SLC1A2), EAAT3 (EAAC1; SLC1A1), EAAT4 (SLC1A6), and 
EAAT5 (SLC1A7); of these, EAAT2 exhibits the highest level of 
expression, is responsible for the largest proportion of total gluta-
mate transport and its functional inactivation raises extracellular 
glutamate to toxic levels (Rothstein et al., 1996; Tanaka et al., 1997; 
Conti and Weinberg, 1999; Rusakov et al., 1999; Danbolt, 2001; 
Kanai and Hediger, 2004; Torres and Amara, 2007; Tzingounis and 
Wadiche, 2007). In both rodents and humans, three functional 
EAAT2 isoforms, named EAAT2a-c, have been reported (Lauriat 
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cerebral ischemia, and multiple sclerosis (Beart and O’Shea, 
2007; Lauriat and McInnes, 2007; Sheldon and Robinson, 2007; 
Rothstein, 2009). How EAAT2 contributes to the pathophysi-
ology of these diseases is at present unclear. In some, perhaps 
most, cases, an excitotoxic mechanism is probable, but in others 
it appears that the contribution of EAAT2 dysfunction is more 
likely to induce changes in synaptic physiology. One necessary 
prerequisite to shed some light on the pathophysiological role(s) 
of EAAT2 is to have firm data on its localization in human cor-
tex. To date, EAAT2 has been described only cursorily in human 
cerebral cortex (see Discussion) and very little is known on its 
distribution and, most importantly, on its cellular and synaptic 
localization. Given this scenario, we used immunocytochemical 
light and electron microscopy to investigate the cellular and syn-
aptic localization of EAAT2a in a collection of bioptic samples of 
human association cortices.
MATERIALS AND METHODS
TISSUE pREpARATION
Human cortical tissue was obtained from surgical specimens of 
13 adult patients with brain tumors and of 1 with an hemorrhagic 
stroke; clinical data are summarized in Table 1. Samples from 7 of 
the 13 cases have been used previously (Conti et al., 1998, 1999; 
Melone et al., 2004, 2005a, 2006). Cortical tissue used in this study 
was not located in the vicinity of the tumor: it was macroscopically 
normal tissue that had to be resected in order to reach deep-seated 
tumors or was included in “tactical lobectomies,” and showed no 
signs of edema. None of the patients suffered form pre- or post-
operative seizures. Informed consent to the surgical procedure was 
obtained in all cases. The approximate location of samples is shown 
in Figure 1.
Specimens used for immunocytochemistry (ICC) were quickly 
(2–3 min) immersed in a cold solution of 4% paraformaldehyde 
(PFA) in 0.1 M phosphate buffer (PB) for 2–3 h and then transferred 
to a fresh solution of 4% PFA (24–48 h at 4°C). Samples were cut 
into small blocks that were further post-fixed (24–72 h at 4°C in 
the same solution), washed several times with PB and stored at 
−20°C in a solution containing 30% glycerol, 30% ethylene glycol, 
30% distilled water and 10% PB 0.4 M. Before cutting, blocks were 
washed several times in PB, cut on a Vibratome into 30–35 μm thick 
sections, and collected in groups of 10; of these, 1 was stained with 
0.1% thionine, and 9 were used for ICC.
For western blotting studies, samples were immediately immersed 
into ice-cold buffer (4 mM Tris, pH 7.4; 0.32 M sucrose; 1 mM 
EDTA; 0.23 mM dithiothreitol; and 1 μM leupeptin and pepstatin 
A) and then homogenized with a glass-Teflon homogenizer in 6 
volume of the same buffer. Synaptic membranes preparation was 
performed as described (Danbolt et al., 1990).
ANTIbODIES
Polyclonal antibodies directed against a synthetic peptide corre-
sponding to the rodent and human amino acid sequence 559–573 
(SADCSVEEEPWKREK; Pines et al., 1992; Arriza et al., 1994) 
of EAAT2a C-terminus (characterized in Rothstein et al., 1994; 
Chen et al., 2004) were used. In our hands, specificity of anti-
bodies (batch #080706) has been demonstrated by the lack of 
immunoreactivity in GLT-1-KO mice (Omrani et al., 2009). In the 
present material, specificity of EAAT2a antibodies was assessed by 
western blottings of synaptic membranes prepared from samples 
of parietal cortex, and by preadsorbing EAAT2a antibodies with 
10−3 M EAAT2a559–573 synthetic peptide in tissue (HBC 961102 
and HBC 980510).
Table 1 | Summary of clinical data.
Case # Cytoar. area Age (year/s) Major symptom(s) Pathology Drug/daily dose/duration (days)1
HBC 961102a 46 59/M Left hemiparesis Frontal metastasis from lung 
carcinoma
Phenobarbital/100 mg/10
HBC 970105a,b 32 56/F High intracranial pressure Hemorrhage from 
capsulostriatal, cavernoma
Phenobarbital/100 mg/35
HBC 980510b,c,d,e 46 60/M High intracranial pressure Frontal meningioma Valproate/1000 mg/30
HBC 980611b,c,d,e 10 64/F High intracranial pressure Orbito-frontal meningioma Valproate/1000 mg/30
HBC 981114d 21 65/M Absent Temporal fossa meningioma Phenobarbital/100 mg/14
HBC 981115 10 64/M Anosmia Orbito-frontal meningioma Phenobarbital/100 mg/21
HBC 981219c,d,e 9 60/F Absent Frontal metastasis from 
breast cancer
Phenobarbital/100 mg/30, 
dexamethasone 16 mg/14
HBC 030129 8 64/M High intracranial pressure Frontal meningioma Valproate/1000 mg/30
HBC 040925d,e 7 58/F Visual field defect Parasagittal meningioma Oxcarbazepine/900 mg/2
HBC 050230 7 37/F Absent Paraventricular, meningioma Oxcarbazepine/900 mg/15, 
dexamethasone 16 mg/15
HBC 050231 8 80/F High intracranial pressure Hemorrhagic stroke None
HBC 070532 19 64/F Absent Parasagittal meningioma Oxcarbazepine/900 mg/2
HBC 070533 10 49/F Left hemiparesis Basal nuclei glioma Oxcarbazepine/900 mg/10, 
dexamethasone 16 mg/10
1Drugs used in perisurgical prophylactic therapy.
a–eCases used in previous studies: aConti et al. (1998); bConti et al. (1999); cMelone et al. (2004); dMelone et al. (2005a); eMelone et al. (2006).Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  3
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IMMUNOCyTOCHEMICAL pROCEDURE
Immunoperoxidase
Sections were treated with H2O2 (1% in PB; 30 min) to remove 
endogenous peroxidase activity, rinsed in PB and pre-incubated in 
10% normal goat serum (NGS, 1 h) with 0.2% Triton X-100 (the lat-
ter only for light microscopic studies). Sections were then   incubated 
Monoclonal antibodies to glial fibrillary acidic protein (GFAP; 
Sigma, St Louis, MO, USA; GA5, G-3893) and polyclonal antibodies 
direct against the C-terminus peptide GATHSTVQPPRPPPPVRDY 
of the rat vesicular glutamate transporter 1 (VGLUT1; Chemicon, 
Temecula, CA, USA; AB5905; characterized in Melone et al., 2005b) 
were also used.
FiGurE 1 | Diagram based on the surgeon’s estimate of cortical resections and on magnetic resonance imaging findings showing the approximate 
location of the cortical samples used in the present study superimposed on Brodmann’s cytoarchitectonic map of the human cerebral cortex. Modified 
from Brodmann (1909).Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  4
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  infiltrated with a mixture of Epon/Spurr resins, sandwiched between 
Aclar films, and polymerized at 60°C for 48 h. After polymerization, 
chips including layers II/III were cut from the wafers, glued to blank 
resin blocks and sectioned with an ultramicrotome. Thin sections 
(60–80 nm) were cut and mounted on 300 mesh nickel grids and 
processed for immunogold labeling as described (Phend et al., 
1992, 1995). Briefly, after treatment with 4% p-phenylenediamine 
in Tris-buffered saline [0.1 M Tris, pH 7.6, with 0.005% Tergitol N 
P-10 (TBST)], grids were washed in TBST (pH 7.6), transferred for 
15 min in 1% NGS in TBST (pH 7.6) and then incubated overnight 
in a solution of TBST (pH 7.6) containing anti-EAAT2a primary 
antibodies (6 μg/ml). Grids were subsequently washed in TBST 
(pH 8.2), transferred for 10 min in 1% NGS in TBST (pH 8.2), 
incubated for 2 h in TBST (pH 8.2) containing IgG anti-rabbit 
secondary antibodies conjugated to 12 nm gold particles (1:20; 
111-205-144, Jackson ImmunoResearch, West Grove, PA, USA) 
secondary antibodies, washed in distilled water, and then stained 
with uranyl acetate and Sato’s lead. Ultrathin labeled sections were 
examined with a Philips EM 208 electron microscope coupled to a 
MegaView-II high resolution CCD camera (Soft Imaging System; 
Munster, Germany). Gold particles were not detected when pri-
mary antiserum was omitted; when normal serum was substi-
tuted for immune serum sparse and scattered gold particles were 
observed, but they did not show any relationship to astrocytic or 
axon   terminal profiles.
The optimal concentration of anti-EAAT2a primary antibodies 
was sought by testing several dilutions; the concentration yielding 
the lowest level of background labeling and still immunopositive 
elements was used to perform the final studies.
WESTERN bLOTTINg
Total amount of protein was determined according to the Bradford 
method (Bradford, 1976) using the Bio-Rad Protein Assay (Bio-Rad 
Laboratories, GmbH, München, Germany) and a Beckman DU 
530 spectrophotometer (Beckman Coulter, Fullerton, CA, USA; 
3–4 measurements). Aliquots of homogenates (2.5–15 μg of total 
protein) were subjected to SDS-PAGE; separated proteins were 
electroblotted onto nitrocellulose filters which were probed with 
antibodies to EAAT2a (0.02 μg/ml). After exposure to peroxidase 
conjugated secondary antibodies (Vector, Burlingame, CA, USA), 
bands were visualized by Bio-Rad Chemidoc and Quantity One 
software using the SuperSignal West Pico (Rockford, IL, USA) 
chemiluminescent substrate (Bragina et al., 2006 for details).
DATA COLLECTION AND ANALySIS
Cytoarchitectonic areas and boundaries were identified on Nissl-
stained sections adjacents to the those used for immunocytochemi-
cal studies, according to Brodmann (1909), von Economo (1928), 
Clarke and Miklossy (1990), Ong and Garey (1990), Rajkowska 
and Goldman-Rakic (1995), Vogt et al. (1995); Semendeferi et al. 
(2001), Scheperjans et al. (2008).
Confocal microscopy
Fields from layers II/III (2 sections/case; 4 cases) were randomly 
selected and Z-axis image stacks were acquired (z-step size 0.6 μm) 
for each fluorescent as 1024 × 1024 pixel images with a planapo 
×63 objective (numerical aperture 1.4) and pinhole 1.0 Airy unit. 
in a solution containing EAAT2a antibodies [0.3–0.5 μg/ml; 2 h 
at room temperature (RT) and overnight at 4°C]. The following 
day, sections were rinsed three times in PB and incubated first in 
10% NGS (15 m) and then in a solution containing anti-rabbit 
biotinylated secondary antibodies (1:150; Vector, Burlingame, CA, 
USA, BA-1000; 1 h at RT). Sections were subsequently rinsed in 
PBS, incubated in avidin–biotin peroxidase complex (ABC Elite 
PK6100, Vector), washed several times in PB, and incubated in 
3,3′-diaminobenzidine tetrahydrochloride (DAB; 0.05% in 0.05 M 
Tris buffer, pH 7.6 with 0.03% H2O2). Method specificity was veri-
fied by substituting primary antibodies with PB or NGS. Sections 
were washed in PB, mounted on gelatin-coated slides, air-dried, 
coverslipped, and finally examined with a Leitz Orthoplan (Wetzlar, 
Germany) microscope.
After completion of ICC procedure, sections from cases HBC 
980611, 981115, and 030129 were post-fixed in 1% osmium tetrox-
ide in PB for 45 m, and contrasted with 1% uranyl acetate in maleate 
buffer (pH 6.0; 1 h). After dehydration in ethanol and propylene 
oxide, sections were embedded in Epon/Spurr resin (Electron 
Microscopy Sciences, Hatfield, PA, USA), flattened between Aclar 
sheets (Electron Microscopy Sciences) and polymerized at 60°C 
for (48 h). Small blocks of tissue containing layers II/III (HBC 
980611 and 030129) and white matter (HBC 981115 and 030129) 
were selected by light microscopic inspection, glued to blank 
epoxy and sectioned with an ultramicrotome (MTX; Research 
and Manufacturing Company Inc., Tucson, AZ, USA). The most 
superficial ultrathin sections (∼60 nm) were collected and mounted 
on 200 mesh copper grids, stained with uranyl acetate and Sato’s 
lead and examined with a Zeiss EM 900 (Carl Zeiss NTS GmbH, 
Oberkochen, Germany).
Immunofluorescence
EAAT2a/VGLUT-1 double-labeling studies were performed on 
sections from cases HBC 050230, 05231, 070532, and 070533. 
Sections were washed in PB, incubated in 10% NGS and 0.2% 
Triton X-100 in PB (1 h) and then in a solution containing a mix-
ture of EAAT2a (0.3 μg/ml) and VGLUT1 (1:1000) primary anti-
bodies (2 h at RT, overnight at 4°C). Sections were washed and 
incubated first in 10% NGS in PB (15 m) and then in a solution 
containing a mixture of affinity-purified fluorescein isothiocyanate 
(FITC, 1:250; Vector; FI1000/J0114)- or tetramethylrhodamine 
isothiocyanate (TRITC, 1:250; Molecular Probes, PoortGebouw, 
The Netherlands, T-2762/6691-1)-conjugated secondary antibod-
ies (90 min). Sections were washed, mounted, air-dried and cov-
erslipped using Vectashield mounting medium (H-1000; Vector) 
and finally examined with a Bio-Rad (Hemel Hempstead, UK) 
Microradiance confocal laser scanning microscope equipped with 
argon (488 nm) and helium/neon (543 nm) lasers. Control experi-
ments with single-labeled sections and sections incubated with 
two primary antibodies and one secondary antibody or with one 
primary and two secondary antibodies revealed neither appreciable 
FITC/TRITC bleed-through nor antibody cross-reactivity.
Immunogold
Sections from cases HBC 980510, 981115, and 030129 were proc-
essed for an osmium-free embedding method (Phend et al., 1995). 
Briefly, dehydrated sections were immersed in propylene oxide, Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  5
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Statistical analysis was performed using GraphPrism v.4.0 
(GraphPad Software, San Diego, CA, USA); α = 0.05.
RESULTS
Examination of Nissl and GFAP-stained sections adjacent to those 
used for EAAT2a studies revealed that they were both devoid of any 
appreciable abnormalities and consistent with previous descrip-
tion of normal tissue (Hansen et al., 1987; Marco et al., 1996). 
EAAT2a-immunoreactivity (ir) in both gray and white matter was 
totally abolished when EAAT2a antibodies were substituted with 
NGS or PB (not shown) or blocked with EAAT2a559–573 synthetic 
peptide (Figure 2A). Western blotting studies of cortical homoge-
nates showed that EAAT2a antibodies recognized a single band of 
∼70 kDa (Figure 2B), consistent with the known molecular weight 
of EAAT2a.
DISTRIbUTION Of EAAT2a-ir IN HUMAN CEREbRAL CORTEx
Light microscopic examination revealed that EAAT2a-ir in pre-
frontal, parietal, temporal, occipital, and cingulofrontal cortical 
areas (areas 46, 8, 9, 10, 7, 19, 21, and 32) was present in all cortical 
layers, without any preferential distribution (Figure 3); in all corti-
ces, small irregular areas of reduced immunostaining were evident 
(Figure 3). In gray matter, EAAT2a-ir consisted of small punctate 
structures scattered in the neuropil (Figures 4A–E); small EAAT2a-
positive (+) cells with intensely stained processes were occasionally 
noticed in layers I and VI, (Figure 4D); EAAT2a+ profiles were 
frequently present along blood vessels (Figure 4E). In the white 
matter underlying the cortex, EAAT2a+ cells, as well as perivascular 
EAAT2a+ profiles (Figures 4F–H), were numerous.
CELLULAR LOCALIzATION Of EAAT2a-ir IN HUMAN CEREbRAL CORTEx
Electron microscopic studies of immunoperoxidase pre-embedded 
material from layers II/III of areas 8 and 10 showed that electron-
dense reaction product was frequently observed in the cytoplasm of 
astrocytes (Figure 5A) and, rarely, in that of neurons (Figure 5B). 
To improve signal/noise ratio, eight frames of each images were 
averaged; microscopic fields were scanned with a pixel size of 
80 nm. Quantitative analysis was performed in randomly selected 
10 μm × 10 μm fields from each 1024 × 1024 pixel image; to achieve 
optimal detection and resolution only images collected at the very 
surface of stained sections were used to study EAAT2a and VGLUT1 
punctate immunostaining (Melone et al., 2005b, 2009). Image 
processing was performed on Photoshop CS2 (Adobe Systems, San 
Jose, CA, USA) and threshold levels were set as described (Melone 
et al., 2005b, 2009). To identify any overlap between EAAT2a-
positive (+) and VGLUT1+ puncta, the channel corresponding to 
EAAT2a was examined first and each positive puncta identified. The 
second channel (corresponding to VGLUT1) was then viewed and 
the presence or absence of overlap was noted for each field.
Pre-embedding electron microscopy
EAAT2a immunopositive profiles were studied from ultrathin 
sections at the surface of the embedded blocks. Quantitative data 
on EAAT2a immunopositive profiles derived from the analysis 
of 3120 μm2 of cortical neuropil (2–4 grids/case; 2 cases) and 
of 1500 μm2 of white matter (3 grids/case; 2 cases). Fields with 
EAAT2a+ profiles were randomly selected and captured at 12,000 
or 20,000×. Microscopic fields used to evaluate EAAT2a localization 
at synapses were selected and captured at original magnifications 
of ×30,000 or 50,000. Micrographs were digitized using a scanner 
connected to a Macintosh platform. Cells and cellular elements 
were identified according to Peters et al. (1991).
Post-embedding immunogold electron microscopy
Ultrathin sections (3 grids/3 cases) were examined at 50,000–85,000× 
and fields that included at least 1 immunolabeled perisynaptic 
astrocytic profile and/or axon terminal associated with an asym-
metric synapse exhibiting a clear AZ–PSD complex were selected 
(Peters et al., 1991; Tyler and Pozzo-Miller, 2001). To determine the 
relative density of EAAT2a in subcellular compartments, astrocytic 
profiles, axon terminals, and pyramidal cell nuclei were identified; 
gold particles within labeled structures were counted and areas were 
calculated using ImageJ version 1.29 software (NIH, Bethesda, MD, 
USA). Background was calculated by estimating labeling density 
over pyramidal cell nuclei (Racz and Weinberg, 2004; Melone et al., 
2009). Particle densities were counted and compared with back-
ground labeling. Gold particles were considered associated with 
plasma membrane if they were within 15 nm of the extracellular 
side of the membrane, and cytoplasmic if they were >25 nm from 
the extracellular side of the membrane. Localization of a plasma 
membrane-associated gold particle with respect to the AZ margin 
was defined as described by Kharazia and Weinberg (1997) and 
Valtschanoff and Weinberg (2001). Briefly, the lateral position of a 
gold particle was defined as the distance along the plasma membrane 
from the AZ edge to the center of the particle (Valtschanoff and 
Weinberg, 2001; Racz and Weinberg, 2004); distance was measured 
using ImageJ software. The distance of gold particles coding for 
EAAT2a from AZ margin in both axon terminals and astrocytic 
processes was normalized to allow data pooling using the equation 
XN = 1 − |x1 − x2|/x1 + x2, where x1 and x2 correspond respectively to 
the distances from the closer and farther edges of the AZ, respectively 
(Racz and Weinberg, 2004).
FiGurE 2 | Method specificity. (A) EAAT2a-ir in human cortex (area 46, HBC 
961102; left) is completely abolished (right) by preincubation of EAAT2a 
antibodies with 10−3 M of EAAT2a559–573 synthetic peptide. (B) Western 
blottings of cortical synaptic membranes (area 7 , HBC 040925) shows that 
EAAT2a antibodies recognize a band of ∼70 kDa among a wide range of total 
protein loaded (from 2.5 to 15.0 μg/lane). Scale bar: 200 μm for (A).Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  6
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17.1 ± 3.4% were myelinated axons and 2.0 ± 0.8% were not iden-
tified (Figure 5J). EAAT2a-ir was never observed in microglial cells 
and oligodendrocytes.
SyNApTIC LOCALIzATION Of EAAT2a-ir IN HUMAN CEREbRAL CORTEx
Confocal and pre-embedding electron microscopic studies
Next, we investigated whether EAAT2a is expressed in the vicinity 
or at some distance from asymmetric synapses by double-labeling 
studies of EAAT2a and VGLUT1 ir, which are typically seen as 
puncta dispersed in the neuropil (Minelli et al., 2001; Alonso-
Nanclares et al., 2004; Melone et al., 2005b, 2009). High resolution 
EAAT2a-ir was never observed in the cytoplasm of microglia cells 
and oligodendrocytes. In the neuropil, EAAT2a-ir was in astro-
cytic processes, axon terminals, and dendrites (Figures 5C–E): a 
quantitative analysis showed that out of 449 EAAT2a+ elements 
(from 126 microscopic fields) 77.1 ± 2.5% were astrocytic processes, 
14.2 ± 2.1% were axon terminals; 2.8 ± 1.1% were dendrites and 
5.4 ± 1.2% were not identifiable (Figure 5F). In the white matter 
underlying areas 8 and 10, EAAT2a-ir was in the cytoplasm and 
processes of numerous fibrous astrocytes (Figures 5G,H), and in 
myelinated axons (Figure 5I); out of 245 positive elements (from 
63 microscopic fields), 81.8  ±  3.2% were astrocytic processes, 
FiGurE 3 | Distribution of EAAT2a-ir in human cerebral cortex. (A–D) EAAT2a-ir in prefrontal [(A) area 46; HBC 980510], parietal [(B) area 7; HBC 050230], 
temporal [(C) area 21; HBC 981114], and cingulofrontal transitional [(D) area 32; 970105] cortices. (A′–D′) Adjacent Nissl-stained sections. Arrowheads indicate sparse 
and irregular patchy areas of limited EAAT2a-ir. Roman numerals indicate cortical layers. WM, white matter. Scale bar: 250 μm for (A–D,A′–D′).Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  7
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Post-embedding immunogold studies
In samples from layers II/III of areas 8, 10, and 46 processed for 
immunogold post-embedding electron microscopy, gold particles 
were observed in both distal astrocytic processes (Figure 7A) and 
axon terminals (Figure 7B). In astrocytic processes contacting 
asymmetric synapses (n = 97) and in axon terminals (n = 46), gold 
particle density was 25.11 ± 3.6 and 2.8 ± 0.4 particles/μm2, respec-
tively, and was significantly higher (two-tailed t-test: P < 0.005 
and P < 0.0001) than background, estimated by calculating gold 
particle density over pyramidal cell nuclei (n = 13; 0.4 ± 0.04 par-
ticles/μm2). Next, we ascertained whether gold particles coding 
for EAAT2a were preferentially localized near the plasma mem-
brane of astrocytic processes and axon terminals by comparing 
the number of gold particles associated to the membrane (within 
15 nm of the extracellular side of the membrane) and of those 
not associated to it (>25 nm from the extracellular side of the 
membrane). In both astrocytic processes and axon terminals, the 
density of membrane-associated gold particles (59.3 ± 4.6 and 
41.9 ± 4.4 particles/μm2, respectively) was much higher than that 
of gold particles not associated to membrane (28.1 ± 5.2 and 
3.4 ± 0.2 particles/μm2; two-tailed t-test: P < 0.0001). The density 
confocal microscopy of EAAT2a (TRITC)/VGLUT1 (FITC) double 
labeled fields from layers II/III of areas 7, 8, 10, and 19 showed 
that red and green puncta were morphologically different and 
separated; however, in all merged images many puncta were at least 
partially yellow (Figures 6A–A″), indicating a spatial overlap of 
the two signals. All signal overlap was taken to indicate EAAT2a 
expression in the vicinity of the glutamatergic synapse (Melone 
et al., 2009); we estimated that 40.3 ± 1.5% of EAAT2a+ puncta 
(n = 2285; 20 microscopic fields) overlapped with VGLUT1+ 
puncta. Electron microscopy confirmed that EAAT2+ profiles 
were both in intimate association with asymmetric synapses and 
far from the synapses (Figure 6B). To better define the organization 
of synapses expressing EAAT2a, we performed a pre-embedding 
electron microscopy analysis of asymmetric synapses (n = 130; 
layers II/III; areas 8 and 10). These studies showed that 67.9 ± 4.0% 
of EAAT2a expressed at asymmetric synapses was in astrocytic 
processes, 17.9 ± 3.3% in axon terminals, while 13.4 ± 2.9% was 
both in astrocytic processes and in axons (Figures 6C–F). Overall, 
these data indicated that about half of cortical EAAT2a is in the 
vicinity of asymmetric synapses and that about 70% of the latter 
is in astrocytic processes.
FiGurE 4 | Light microscopic analysis of EAAT2a-ir in human cerebral cortex. 
(A–E) In cortical gray matter (area 46; HBC 961102) EAAT2 ir is characterized by 
widespread EAAT2a + puncta dispersed in the neuropil [(A) layers II/III; (B) layer IV] 
or outlining unstained cells bodies [(C) layer II/III], rare intensely stained cells in 
layer I (D), and perivascular profiles (E) (layers II/III). (F–H) In the white matter 
underlying the cortex (area 32; HBC 970105) EAAT2a-ir is in cells resembling 
astrocytes (F,G) and in perivascular profiles (H). bv, blood vessel. Arrowheads in 
(A,B) indicate patchy areas of limited EAAT2a-ir; arrows in (D,F,G) point to 
intensely stained astrocyte-like cells; and arrowheads in (E,H) indicate EAAT2 ir 
perivascular profiles. Scale bars: 20 μm for (A–E,G–H); 50 μm for (F).Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  8
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axon terminals (n = 46), particles were also distributed over a wide 
distance range (mean distance: 277.1 ± 36.9 nm; n = 51) and were 
concentrated at 40–160 nm from AZ edge with a peak at 60 nm 
(Figures 7F–H). The position of the EAAT2a coding particles was 
then normalized such that 0 corresponded to the AZ edge and 1.0 
to the point along the perimeter equidistant from both AZ edges 
in the case of axon terminals or from the AZ edge ipsilateral to 
the astrocytic process displaying gold particles. Normalized data 
of membrane-associated gold particles was significantly higher 
in astrocytic processes than in axon terminal (two-tailed t-test: 
P < 0.005). Finally, we measured the distance on the plasma mem-
brane between gold particles coding for EAAT2a and AZ edges. In 
astrocytic processes contacting asymmetric synapses (n = 99), gold 
particles (n = 108) were found over a wide distance range (mean 
distance: 360.9 ± 23.4 nm) and were concentrated at 60–220 nm 
from the AZ edge, with a peak at 120–140 nm (Figures 7C–E). In 
FiGurE 5 | Cellular localization of EAAT2a-ir in human cerebral cortex 
studied by pre-embedding electron microscopy. (A–E) In gray matter, 
EAAT2 ir is localized to astrocytes (A) and rarely in neurons (B), where it is 
closely associate to endoplasmic reticulum (arrows). In the neuropil, EAAT2a 
is observed in astrocytic processes (C), axon terminals (D), and dendrites (E). 
Area 10; case HBC 980611. (F) Quantification of EAAT2a+ profiles in gray 
matter. (G–i) In white matter, EAAT2 ir is in fibrous astrocytes [arrowheads in 
(G)] and along their fibrous processes [(G′); enlargement from the framed 
region in (G)], in astrocytic processes (H) and in myelinated axons (i). Area 10; 
case HBC 981115. (J) Quantification of EAAT2a+ profiles in white matter. Ax, 
myelinated axon; AxT, axon terminal; AsP , astrocytic process; Den, dendrite; 
ER, endoplasmic reticulum; f, astrocyte fibrous filament; G, Golgi apparatus; 
r, ribosomes; U, unidentified profiles. Scale bars: 0.8 μm for (A,G); 0.1 μm for 
(B); 0.25 for (C); 0.15 μm for (C,D); 0.3 μm for (G′,i); and 0.4 for μm (J).Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  9
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DISTRIbUTION Of EAAT2 IN CEREbRAL CORTEx: COMpARISON WITH 
pREvIOUS STUDIES AND METHODOLOgICAL CONSIDERATIONS
We exposed bioptic samples of human neocortex to specific anti-
bodies directed against a synthetic peptide corresponding to the 
common rodent and human EAAT2a C-terminal sequence 559–573 
(Pines et al., 1992; Arriza et al., 1994). Studies in EAAT2 knock-
out mice showed that EAAT2a-ir revealed by these antibodies is 
genuine (Chen et al., 2004; Omrani et al., 2009). In addition, we 
performed conventional controls employed in human studies, i.e., 
western blotting of synaptic membranes and pre-absorption with 
EAAT2a synthetic peptide (Saper and Sawchenko, 2003; Fritschy, 
2008). These data indicated that EAAT2a-ir detected in our experi-
mental conditions is specific.
The distribution of EAAT2 ir has been described in previous 
light microscopic studies, with different results. In some reports, 
EAAT2 ir is strong in somata and proximal processes of glial-like 
cells irregularly scattered in cortical parenchyma, without a diffuse 
neuropilar staining (“irregular pattern”; Milton et al., 1997; Fray 
et al., 1998; Proper et al., 2002; Furuta et al., 2005; Matute et al., 
2005; Williams et al., 2005), whereas in others EAAT2 is described 
in punctate structures scattered in the neuropil (“regular pattern”; 
Rothstein et al., 1995; Bar-Peled et al., 1997; Ikematsu et al., 2001; 
Bjornsen et al., 2007). Our results agree with those reporting a “regu-
lar” pattern of EAAT2 ir. Differences in immunocytochemical detec-
tion in human material may be accounted for by primary antibodies 
showed that membrane-associated EAAT2a of axon terminals 
or astrocytic processes was at mean tangential distance from AZ 
edge of 0.31 ± 0.03 and 0.35 ± 0.02, respectively. Two-tailed t-test 
showed that the two populations were comparable (P > 0.05). 
These studies showed that the density of membrane-associated 
EAAT2a molecules is higher in astrocytic processes than in axon 
terminals and indicated that in both axon terminals and astro-
cytic processes contacting asymmetric synapses most EAAT2 is 
concentrated in a membrane region extending for about 300 nm 
from the AZ edge.
DISCUSSION
These studies provide the first detailed description of the cellular 
and synaptic localization of EAAT2a in human cerebral cortex. 
They show that: (1) EAAT2a is expressed in all layers, where it is 
localized to astrocytes and neurons. Astrocytic processes and axon 
terminals are ∼75 and ∼15% of all EAAT2a-positive elements, 
respectively; (2) about half of cortical EAAT2 is in the vicinity 
of cortical synapses and 70% of it is in astrocytic processes; (3) 
in post-embedding electron microscopic studies the density of 
gold particles coding for EAAT2a in astrocytic processes is about 
10 times higher than in axon terminals; and (4) in both axon 
terminals and astrocytic processes most EAAT2a is concentrated 
in a membrane region extending for ∼300 nm from the active 
zone edge.
FiGurE 6 | Synaptic localization of EAAT2a-ir in human cerebral cortex: 
confocal and pre-embedding electron microscopic studies. (A) 
Simultaneous visualization of EAAT2a (red) and VGLUT1 (green) shows variable 
degree of overlap between the two signals; (A′,A″) are enlargements of framed 
regions in (A). Area 11; HBC 070533. (B) Pre-embedding electron microscopy 
confirms the presence of EAAT2 ir in intimate association with (arrowheads) and 
far from (arrow) asymmetric synapses. Area 8, HBC 030129. (C–E) Examples of 
EAAT2a localization to (1) astrocytic processes in intimate association with 
asymmetric synapses whose axon terminal is not EAAT2a-ir (C); (2) astrocytic 
processes in close association with EAAT2a+ axon terminals forming 
asymmetric synapses [arrow in (F)]; and (3) axon terminals making asymmetric 
synapses [arrow in (E)]. Area 8, HBC 030129. (F) Proportion of the different 
organizational models. Den, dendrite; AsP astrocytic process; AxT, axon 
terminals. Scale bars: 1 μm for (A–A″); 0.25 μm for (B–E).Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  10
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used and by several confounding factors, i.e., nature of the samples 
(autoptic vs bioptic), cause of death, postmortem interval (PMI; for 
autoptic samples), presence of brain diseases, fixative used for tissue 
preservation (Lewis, 2002). As far as EAAT2 studies are concerned, 
there is evidence that the presence and nature of pathological proc-
esses may be responsible for different patterns of immunoreactivity 
(Ikematsu et al., 2001; Bjornsen et al., 2007); since we did not detect 
any appreciable abnormality in Nissl and GFAP-stained sections, 
FiGurE 7 | Synaptic localization of EAAT2a-ir in human cerebral cortex: 
post-embedding immunogold studies. (A,B) Visualization of gold particles 
coding for EAAT2a in astrocytic processes (A) and axon terminals (B). Arrows 
point to several gold particles dispersed in the cytoplasm or associated to 
membranes. (C–H) Localization of membrane-associated gold particles 
coding for EAAT2a in astrocytic processes (C,D) and axon terminals (F,G) in 
relation to the AZ–PSD complex of asymmetric synapses. (E,H) Graphs show 
distance of gold particles detected in astrocytic processes (E) and axon 
terminals (F) from the AZ edge of terminals forming asymmetric synapses. 
The y-axis indicates the density of particles for each bin (20 nm), obtained by 
dividing the number of particles counted in each bin by the number of profiles 
extending that far. Den, dendrite; AsP , astrocytic process; AxT, axon terminal; 
AZ, active zone; PSD, post-synaptic density. Scale bars: 60 nm for (A,B); 
100 nm for (C,D,F,G).Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  11
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these factors do not seem to apply to our material. Instead, it is 
worth noting that the “irregular pattern” is described in studies in 
which either autoptic samples with long PMI (Milton et al., 1997; 
Fray et al., 1998; Proper et al., 2002; Furuta et al., 2005; Matute et al., 
2005) or different antibodies (Milton et al., 1997; Fray et al., 1998; 
Proper et al., 2002; Furuta et al., 2005; Williams et al., 2005) were 
used. Interestingly, Proper et al. (2002) showed in autoptic samples 
that longer PMI are associated to highly irregular EAAT2 pattern. 
Since EAAT2 detection is sensitive to fixative agents (Chen et al., 
2004; Melone et al., 2009), it is likely that long storage of samples in 
formalin, a common feature of studies using autoptic samples which 
exerts a masking effect on EAAT2 epitopes, is another important 
source of variability of EAAT2 immunostaining. The view that the 
nature of samples and antibodies used are major determinants of 
differences reported in previous studies of EAAT2 distribution is 
supported by the observation that two studies reporting a “regular” 
pattern used the same antibodies used here in autoptic samples 
with short PMIs (Rothstein et al., 1995; Bar-Peled et al., 1997). In 
this context, it should be emphasized that we used bioptic material, 
which permits to fix tissue immediately and thus to rule out an 
important confounding factor, i.e., PMI. Thus, it appears that use 
of bioptic material immediately fixed with gentle fixative solutions 
and conserved in a fixative-free solution and of well-characterized 
antibodies may have allowed a good preservation of antigenicity 
and a better detection of EAAT2a-ir in our material.
CELLULAR AND SyNApTIC LOCALIzATION Of EAAT2a IN 
HUMAN NEOCORTEx
The results on the cellular localization show that EAAT2 is highly 
expressed by astrocytes and that numerous EAAT2a-ir elements 
are axon terminals, whereas we did not notice EAAT2 ir in oli-
godendrocytes or microglial cells.
Cellular localization of EAAT2 has been rarely studied at the 
electron microscopic level in human cortex. Bjornsen et al. (2007) 
reported that in bioptic human epileptogenic hippocampus EAAT2 
was exclusively in astrocytic somata and processes. As described in 
Results, we showed that ∼15% of all EAAT2 ir processes were neuro-
nal. Procedural differences between their study and the present one 
concern fixation, as they fixed material with PFA and picric acid and 
post-fixed it with acrolein, whereas we used PFA only. Studies in rats 
showed that neuronal EAAT2 is visualized in all experimental condi-
tions in which strong fixatives are avoided (Chen et al., 2004; Melone 
et al., 2009). It is therefore likely that the difference between the 
observations of Bjornsen et al. (2007) and ours are accounted for by 
the different fixative procedure employed. These data are in line with 
evidence gathered in rats showing that some EAAT2 is expressed by 
neurons (Chen et al., 2004; Furness et al., 2008; Holmseth et al., 2009; 
Melone et al., 2009; see also Berger et al., 2005; and de Vivo et al., 
2010). Analysis of EM data also revealed a remarkable heterogeneity 
in the organization of asymmetric synapses expressing EAAT2a, as 
they showed that at asymmetric synapses expressing EAAT2a the 
transporter is localized in astrocytic processes located near axon 
terminals expressing EAAT2a, in axon terminals, and in astrocytic 
processes located near axon terminals not expressing EAAT2a. The 
observation that different excitatory synapses have different organi-
zational models of GLT-1-mediated Glu uptake suggests that they 
may have different functional features.
Post-embedding immunogold electron microscopic studies 
revealed that the density of membrane-associated EAAT2a mol-
ecules in astrocytic processes is about 10 times higher than in axon 
terminals. Assuming that gold particle density is linearly corre-
lated to the number of functional molecules, the evidence that the 
density of EAAT2a is higher in astrocytes than in axon terminals 
forming asymmetric synapses indicates that astrocytic EAAT2a is 
responsible for the largest fraction of glutamate uptake at cortical 
synapses. We studied the distribution of gold particles coding for 
GLT-1a in both astrocytic processes contacting asymmetric syn-
apses and in GLT-1a+ terminals forming asymmetric synapses. 
These studies showed that in both astrocytic processes and axon 
terminals most EAAT2a was in a membrane region extending for 
about 250–300 nm from AZ margin. This membrane region is 
considered perisynaptic (Lujan et al., 1996; Barthó et al., 2004). 
Thus, at cortical synapses, the regions of high EAAT2a concen-
tration appear to be largely perisynaptic, whereas the regions of 
lower concentration are extrasynaptic. The demonstration that a 
large fraction of neuronal and astrocytic EAAT2a is localized at 
perisynaptic sites parallels our previous findings in rats (Melone 
et al., 2009). Perisynaptic sites are well suited for modulating the 
concentration of glutamate in the cleft, as suggested by the observa-
tion that in most experimental paradigms antagonizing glutamate 
transporters enhances synaptic currents (Tzingounis and Wadiche, 
2007), and for regulating the amount of glutamate allowed to reach 
presynaptic receptors (e.g., Omrani et al., 2009). Both mechanisms 
may contribute to modulating synaptic strength.
Several laboratories have reported the expression of glutamate 
transporters by oligodendrocytes and microglial cells. Although 
inconsistencies do exist, results of rodent studies indicate that 
EAAC1 (EAAT3) is the main oligodendrocytic glutamate trans-
porter, and that GLT-1 (EAAT2) is expressed more robustly during 
development or in juvenile brains (Domercq et al., 1999; Matute 
et al., 2007; Desilva et al., 2009). As far as human cerebral cortex is 
concerned, Desilva et al. (2007) reported that EAAT2 was highly 
expressed in fetal white matter oligodendrocytes and during early 
development and virtually disappeared by two postnatal months. 
The results of our studies are in line with the findings of Desilva 
et al. (2007). Even considering the resolution limits of immuno-
cytochemical techniques, these data indicate that EAAT2 is either 
poor or totally absent in human neocortical oligodendrocytes, sug-
gesting that the proposed role of glutamate transport alterations 
in multiple sclerosis and other demyelinating diseases (Pitt et al., 
2003; Matute et al., 2007) is either mediated by glutamate transport-
ers other than EAAT2 or that EAAT2 expression is re-activated in 
adulthood. The lack of EAAT2a-ir in microglial cells reported here 
is in line with the notion that in these cells expression of glutamate 
transporters, including EAAT2, is normally activation-dependent 
and associated to factors generated during pathological events in 
the brain (Chrétien et al., 2002; Persson et al., 2005, 2009; Bonifati 
and Kishore, 2007; Tilleux and Hermans, 2007).
Of RATS AND MEN: COMpARATIvE ANALySIS Of EAAT2a DISTRIbUTION 
AND SOME IMpLICATIONS
We have recently studied the cellular and synaptic localization of 
EAAT2a (GLT-1a) in the neocortex of rats (Melone et al., 2009). 
We found that in optimal conditions: (1) ∼25% GLT-1a+ profiles Frontiers in Neuroanatomy  www.frontiersin.org  January 2011  | Volume 4  | Article 151  |  12
Melone et al.  EAAT2 in human cerebral cortex 
glial cell processes. Neuroscience 51, 
295–310.
Dehaene, S., Duhamel, J.-R., Hauser, M. 
D., and Rizzolatti, G. (2005). From 
Monkey Brain to Human Brain. 
Cambridge, MA: MIT Press.
Desilva, T. M., Kabakov, A. Y., Goldhoff, 
P. E., Volpe, J. J., and Rosenberg, P. A. 
(2009). Regulation of glutamate trans-
port in developing rat oligodendro-
cytes. J. Neurosci. 29, 7898–7908.
Desilva, T. M., Kinney, H. C., Borenstein, 
N. S., Trachtenberg, F. L., Irwin, N., 
Volpe, J. J., and Rosenberg, P. A. (2007). 
The glutamate transporter EAAT2 is 
transiently expressed in developing 
human cerebral white matter. J. Comp. 
Neurol. 501, 879–890.
de Vivo, L., Melone, M., Rothstein, J. D., 
and Conti, F. (2010). GLT-1 promoter 
activity in astrocytes and neurons of 
mouse hippocampus and somatic 
sensory cortex. Front. Neuroanat. 3:31. 
doi: 10.3389/neuro.05.031.2009
Domercq, M., Sánchez-Gómez, M. V., 
Areso, P., and Matute, C. (1999). 
Expression of glutamate transporters 
in rat optic nerve oligodendrocytes. 
Eur. J. Neurosci. 11, 2226–2236.
Fray, A. E., Ince, P. G., Banner, S. J., Milton, 
I. D., Usher, P. A., Cookson, M. R., and 
Shaw, P. J. (1998). The expression of 
the glial glutamate transporter protein 
EAAT2 in motor neuron disease: an 
immunohistochemical study. Eur. J. 
Neurosci. 10, 2481–2490.
Fritschy, J. M. (2008). Is my antibody-
staining specific? How to deal with 
pitfalls of immunohistochemistry. 
Eur. J. Neurosci. 28, 2365–2370.
Furness, D. N., Dehnes, Y., Akhtar, A. Q., 
Rossi, D. J., Hamann, M., Grutle, N. 
J., Gundersen, V., Holmseth, S., Lehre, 
of SIVmac251-infected macaques. 
Neuropathol. Appl. Neurobiol. 28, 
410–417.
Clarke, S., and Miklossy, J. (1990). 
Occipital cortex in man: organization 
of callosal connections, related myelo- 
and cytoarchitecture, and putative 
boundaries of functional visual areas. 
J. Comp. Neurol. 298, 188–214.
Conti, F., Barbaresi, P., Melone, M., and 
Ducati, A. (1999). Neuronal and glial 
localization of NR1 and NR2A/B 
subunits of the NMDA receptor in the 
human cerebral cortex. Cereb. Cortex 
9, 110–120.
Conti, F., and Hicks, T. P. (eds). (1996). 
Excitatory Amino Acids and the 
Cerebral Cortex. Cambridge, MA: 
MIT Press.
Conti, F., Melone, M., DeBiasi, S., Minelli, 
A., Brecha, N. C., and Ducati, A. (1998). 
Neuronal and glial localization of 
GAT-1, a high affinity g-aminobutyric 
acid plasma membrane transporter, in 
human cerebral cortex; with a note on 
its distribution in monkey cortex. J. 
Comp. Neurol. 396, 51–63.
Conti, F., and Weinberg, R. J. (1999). 
Shaping excitation at glutamater-
gic synapses. Trends Neurosci. 22, 
451–458.
Danbolt, N. C. (2001). Glutamate uptake. 
Prog. Neurobiol. 65, 1–105.
Danbolt, N. C., Pines, G., and Kanner, B. I. 
(1990). Purification and reconstitution 
of the sodium- and potassium-cou-
pled glutamate transport glycopro-
tein from rat brain. Biochemistry 29, 
6734–6740.
Danbolt, N. C., Storm-Mathisen, J., and 
Kanner, B. I. (1992). An [Na+–K+]
coupled  l-glutamate transporter 
purified from rat brain is located in 
human epileptogenic hippocampus: 
inadequate explanation for high extra-
cellular glutamate during seizures. 
Neurobiol. Dis. 25, 319–330.
Bonifati, D. M., and Kishore, U. (2007). 
Role of complement in neurodegen-
eration and neuroinflammation. Mol. 
Immunol. 44, 999–1010.
Bradford, M. M. (1976). A rapid and 
sensitive method for the quantitation 
of microgram quantities of protein 
utilizing the principle of protein-dye 
binding. Anal. Biochem. 72, 248–254.
Bragina, L., Melone, M., Fattorini, 
G., Torres-Ramos, M., Vallejo-
Illarramendi, A., Matute, C., and 
Conti, F. (2006). GLT-1 down-reg-
ulation induced by clozapine in rat 
frontal cortex is associated with synap-
tophysin up-regulation. J. Neurochem. 
99, 134–141.
Brodmann, K. (1909). Vergleichende 
Lokalisationslehre des Grosshirnrinde 
in ihren Prinzipien dargestellt auf 
Grund des Zellenbaues (Translated 
and edited by L. J. Garey. Localization 
in the Cerebral Cortex. London: Smith-
Gordon, 1994). Leipzig: Barth Verlag.
Chen, W., Mahadomrongkul, V., Berger, U. 
V., Bassan, M., DeSilva, T., Tanaka, K., 
Irwin, N., Aoki, C., and Rosenberg, P. 
A. (2004). The glutamate transporter 
GLT1a is expressed in excitatory axon 
terminals of mature hippocampal 
neurons. J. Neurosci. 24, 1136–1148.
Chrétien, F., Vallat-Decouvelaere, A. 
V., Bossuet, C., Rimaniol, A. C., Le 
Grand, R., LePavec, G., Créminon, 
C., Dormont, D., Gray, F., and Gras, 
G. (2002). Expression of excitatory 
amino acid transporter-2 (EAAT-2) 
and glutamine synthetase (GS) in 
brain macrophages and microglia 
REfERENCES
Alonso-Nanclares, L., Minelli, A., Melone, 
M., Edwards, R. H., DeFelipe, J., and 
Conti, F. (2004). Perisomatic gluta-
matergic axon terminals: a novel fea-
ture of cortical synaptology revealed 
by vesicular glutamate transporter 1 
immunostaining. Neuroscience 123, 
547–556.
Arriza, J. L., Fairman, W. A., Wadiche, J. 
I., Murdoch, G. H., Kavanaugh, M. P., 
and Amara, S. G. (1994). Functional 
comparisons of three glutamate 
transporter subtypes cloned from 
human motor cortex. J. Neurosci. 14, 
5559–5569.
Bar-Peled, O., Ben-Hur, H., Biegon, A., 
Groner, Y., Dewhurst, S., Furuta, A., and 
Rothstein, J. D. (1997). Distribution 
of glutamate transporter subtypes 
during human brain development. J. 
Neurochem. 69, 2571–2580.
Barthó, P., Payne, J. A., Freund, T. F., and 
Acsády, L. (2004). Differential distri-
bution of the KCl cotransporter KCC2 
in thalamic relay and reticular nuclei. 
Eur. J. Neurosci. 20, 965–975.
Beart, P. M., and O’Shea, R. D. (2007). 
Transporters for l-glutamate: an 
update on their molecular pharmacol-
ogy and pathological involvement. Br. 
J. Pharmacol. 150, 5–17.
Berger, U. V., DeSilva, T. M., Chen, W., 
and Rosenberg, P. A. (2005). Cellular 
and subcellular mRNA localization 
of glutamate transporter isoforms 
GLT1a and GLT1b in rat brain by 
in situ hybridization. J. Comp. Neurol. 
492, 78–89.
Bjornsen, L. P., Eid, T., Holmseth, S., 
Danbolt, N. C., Spencer, D. D., and 
de Lanerolle, N. C. (2007). Changes 
in glial glutamate transporters in 
cerebral cortex, and the theme is still far from being clarified. A 
large body of comparative studies has evidenced both similarities 
and differences (e.g., Dehaene et al., 2005; Kaas and Preuss, 2007; 
Passingham, 2008) and it is not clear how to capture them. In this 
context, our data add the observation that the major high-affinity 
plasma membrane transport system for the transmitter released at 
the majority of cortical synapses, including cortico-cortical syn-
apses, is similar in rats and humans. Second, usefulness of animal 
models of human neuropsychiatric diseases is often questioned, 
based on the view that anatomical, chemical and functional features 
of animals used in such studies, usually rats, differ from those of 
human brains. As the present observations showed that the distri-
bution and localization of EAAT2a are virtually identical in rats and 
humans, they also indicate that animal models aimed at defining 
the role of EAAT2a may be of significant help in our understanding 
of the pathophysiology of numerous neuropsychiatric diseases of 
great clinical relevance.
ACkNOWLEDgMENTS
Supported by MIUR and Università Politecnica delle Marche.
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was neuronal; (4) the density of gold particles coding for GLT-1a 
was much higher in astrocytic processes than in axon terminals; 
and (5) in both astrocytic processes and axon terminals most 
gold particles were localized in a membrane region extending for 
about 250 nm from active zone margin, with a peak at 140 nm 
for astrocytic processes and at 80 for axon terminals. The present 
findings indicate that in human cortex the distribution and locali-
zation of EAAT2a are similar to those of rats. Although little is 
known on the function of EAAT2a-mediated glutamate uptake 
in human cortex and on its regulation, available evidence seems 
to indicate that most functional attributes are similar to those 
described in mice and rats (Danbolt, 2001). Thus, the distribution, 
localization and function of EAAT2a appears virtually identical 
in both species.
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